Xenon Pharmaceuticals (XENE) Operating Leases (2019 - 2026)

Xenon Pharmaceuticals (XENE) has 8 years of Operating Leases data on file, last reported at $5.9 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 18.69% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $5.9 million, a 18.69% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, down 16.14% from the prior year.
• Operating Leases for Q1 2026 stood at $5.9 million, down from $6.4 million in the prior quarter.
• Over the last five years, Operating Leases for XENE reached as high as $10.4 million in Q1 2023 and fell as low as $5.9 million in Q1 2026.
• Historically, Operating Leases has averaged $8.3 million across 5 years, with a median of $8.2 million in 2022.
• Across the five-year window, Operating Leases jumped 185.91% in 2022 and dropped 20.39% in 2024, its largest moves.
• Year by year, Operating Leases stood at $9.9 million in 2022, then declined by 3.45% to $9.6 million in 2023, then fell by 20.39% to $7.6 million in 2024, then decreased by 16.14% to $6.4 million in 2025, then retreated by 7.52% to $5.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $5.9 million in Q1 2026, $6.4 million in Q4 2025, and $6.8 million in Q3 2025.